Open AccessEffect of Astaxanthin supplementation on cognitive function and depression in Patients with Type 2 Diabetes Mellitus
Publication year - 2020
Publication title -
taḥqīqāt-i niẓām-i salāmat
Language(s) - English
Resource type - Journals
eISSN - 2783-4093
pISSN - 2322-5564
DOI - 10.32592/hsr.2020.15.4.107
Subject(s) - beck depression inventory , depression (economics) , placebo , astaxanthin , medicine , diabetes mellitus , type 2 diabetes , randomized controlled trial , type 2 diabetes mellitus , cognition , physical therapy , gastroenterology , psychiatry , anxiety , endocrinology , biology , carotenoid , alternative medicine , botany , pathology , economics , macroeconomics
Background: The oral administration of Astaxanthin may decrease depression symptoms and improved cognitive function through its beneficial effects on inflammation, and oxidative stress. Objective: This study was designed to assess whether Astaxanthin supplementation can reduce symptoms of depression and increase MMSE score in patients with Type 2 Diabetes Mellitus. Methods: This randomized, double-blind, placebo-controlled clinical trial was performed in 44 patients between 30 and 60 y of age with a diagnosis of type 2 diabetes. Patients were randomly assigned to receive either a single capsule of 8 mg of Astaxanthin /day (n = 22) or placebo (n = 22) for 8 wk. The primary [Beck Depression Inventory (BDI), which examines depressive symptoms] and secondary (Mini-Mental State Examination (MSSE) score, which evaluates cognitive function) outcomes were assessed. Results: After 8 week of intervention, Mini-Mental State Examination baseline score was signicantly improved only in the group treated with Astaxanthin, during study (p < 0.01). But no significant reduction in the Beck Depression Inventory (BDI) was observed in both group. Conclusion: Overall, Astaxanthin supplementation of patients with diabetes for 8 weeks had beneficial effects on the MMSE score. Key words: Astaxanthin, Cognitive function Depression